



Synthesis and Antiplatelet of 2-(ethyl amino acid esters), Amino pyridyl 1,3- oxazine

M.S Al-Ajely

Chemistry Dept. College of Education,
Mosul University, Mosul-Iraq

Abstract

2-(N-glycyl ,Alanyl , leucinyll , isoleucinyll , methionyl , phenyl alanyl , vilinyl methyl ester) , 2-Amino and 4- Amino pyridyl -1,3- Benzoxazine -4- one were synthesized from the reaction of the corresponding amino acids ester , Amino pyridines with methyl cyano salicylate using improved method. The resulted benzoxazine derivative were tested for their Antiplatelet inhibitory activity , their IR , NMR (^1H , ^{13}C) were also studied and checked by elemental analysis.

Keywords: Antiplatelet, 1,3 oxazine, amino acid esters inhibitory activity

Council for Innovative Research

Peer Review Research Publishing System

Journal: Journal of Advances in Chemistry

Vol 2, No. 2


editor@cirworld.com

www.cirworld.com, member.cirworld.com



Introduction

Some researchers prepared amino oxazine compounds from the reaction of malonyl chloride and alkyl cyanamide¹. Some amino acid ester derivatives of 1,3-benzoxazine were prepared from the reaction of 7-chloro-2-alkyl thio-1,3-pyranoxazine-4-one with the corresponding amino acid esters². Some 1,3-pyranoxazine compounds were prepared and showed antimicrobial activities against broad spectrum of bacteria and fungi^{3,4}. 7-chloro-2-methyl thio-2-ethyl carbazate of 1,3-pyranoxazine was found to have anti tumor activities according to joint research with (NCI)⁵. Several types of 7 and 2-disubstituted amino acid esters and peptide derivatives of 1,3-pyranoxazine were found to have antibacterial activities^{6,7}. 2-Morpholino substituted benzoxazine compounds were prepared from the reaction of substituted Salicylic acid, triphenyl phosphine dibromide and lead thiocyanate with morpholine. This morpholino 1,3-benzoxazine product gave significant antiplatelet activity⁸. Accordingly this finding which may help prevent blood clots in heart attack patient received national recognition especially in Australia, So research in medicinal chemistry hoped to improve drugs that thin the blood for heart attack, strokes and angina (chest pain) sufferers. The above investigation gave early biological results and encourages us to develop new drugs that may overcome of the side effects associated with existing drugs and that is the main of our investigation in preparing new derivatives of 1,3-benzoxazines.



$R_1 = H$

2 = -CH₃

3 = -CH₃CH₂CHCH₃

4 = -CH₂CH(CH₃)₂


5 = -CH₂CH₂SCH₃

6 = -CH₂Ph

7 = -CHRNH =

8 = -CH(CH₃)₂

9 =



(Scheme 1)

Experimental

All melting points were measured using stuart scientific(smp3) melting point apparatus and are uncorrected.

IR spectra were measured using Perkin Elmer FTIR instrument, ^1H , ^{13}C NMR spectra were performed using Bruker Ac 200 MHz spectrometer at 200 and 50 MHz respectively, All ^1H and ^{13}C NMR spectral result are recorded as chemical shifts (δ) and in the case of CDCl_3 are relative to internal TMS while chemical shifts recorded in DMSO-d_6 are relative to the solvent peak of 2.5 and 39.4ppm respectively. Elemental analysis were measured in chemical and micro analytical services Pty. Ltd. (Belmont) victoria, Australia

Amino acid methyl ester Hydrochloride salts

General procedure

Following the procedure of pirkle et al⁹. The amino acid (11.0mmol) was combined with anhydrous methanol(500ml) in 100ml round bottomed flask equipped with stirring bar. The mixture was cooled to 0°C in an ice/water bath for 30 min, thionyl chloride(1.1equivalent) was then added dropwise with vigorous stirring. The flask was sealed with a latex balloon and stirring continued for 24h. The resulting clear solution was concentrated in vacuo to a volume of approximately 10ml. On cooling in ice, the methyl ester hydrochloride precipitated as a white solid which was collected, washed with ether then recrystallised from appropriate solvent. The purified products were characterised by melting point, ^1H , ^{13}C NMR.

Amino acid methyl ester

General procedure¹⁰

The amino acid ester hydrochloride salt (10mmol) was combined with (chloroform 910ml) in 50ml round bottom flask. To the stirred solution was added dropwise a solution of triethylamine (1.0equivalent) in chloroform (10ml), the mixture then stirred for 4h at room temperature. The mixture was heated at 70°C for 1h then cooled to room temperature and concentrated in vacuo to a white solid. The solid was diluted with ether, filtered and washed with a further 10ml of ether. Concentration of the ether, filtered and washed with a further 10ml of ether. Concentration of the ether filtrate in vacuum gave the amino acid ester free amine.

Synthesis of O-cyno salicylate ethyl ester

Following the same published procedure¹¹ of the reaction between cyanogen bromide and ethyl salicylate, the distillation of the final solution was carried out under reduced pressure. The first fraction which distilled at 64 °C and a pressure of 3.5×10^{-2} was mainly of unreacted ethyl salicylate.



The second fraction which distilled at 64 oC and a pressure of 3.5×10^{-2} was found as a mixture of the un reacted salicylate and some of dimethyl cyanate. The third fraction distilled at 78 oC and a pressure of 3.6×10^{-2} was found as pure cyanosalicylate.

Synthesis of 2-(N-amino acid methyl ester)-1,3-Benzoxazine-4-ones

General procedure 12

The amino acid ester (0.01 mol) was combined with dry acetonitrile (20ml) in 50 ml round bottom flask equipped with dropping funnel and calcium chloride tube. The flask was surrounded with an ice cooled water maintained at 0oC, while the cyanosalicylate (0.01) was dissolved in 20 ml of dry acetonitrile in separating funnel. Addition of the cyanosalicylate solution to the stirred amino acid ester was completed within one hour. After the complete addition of the cyanosalicylate, the reaction mixture was stirred for further 3hs maintaining the temperature all the time at 0oC. The reaction mixture was left to stand on deep freezing for 12 h. The precipitated solid was washed with ether and recrystallised three times from petroleum ether (60-80oC) then from toluene.

2-(N-glycylmethyl ester)-1,3- Benzoxazine-4-one(compound 1)

White crystalline solid, (70% yield) m.p. 192-194oC; $^1\text{H NMR}$ (CDCl_3) δ 10.59 (s1H NH), 8.11, 8.07 (d 1 H), 7.60 (t 1 H), 7.3 (t 1 H), 7.16 (d 1 H) for aromatic protons, 6.29 (s1 H NH), 4.35 (d 3 H OCH₃) 3.80 (d2HCH₂)₂ forms compound; $^{13}\text{C NMR}$ (CDCl_3) δ 168.34.4, 166.23, 168.34.4, 166.23, 155.34, 153.89, 155.34, 153.4, 155.34, 153.89, 136.08, 134.31, 132.27, 127.74, 126.28.84, 53.71, 49.56; IR (KBr) 3473.30 (NH), 1748 (CO ester) 36, 1697.51 (CO of Oxazine ring), 1573 (C=N); Anal. Calcd. For C₈H₉N₃O₃; 56.41, H; 4.30, N; 11.96 Found C; 56.50, H; 4.41, N; 12.03.

2-(N-Alanylmethyl ester)-1,3- Benzoxazine-4-one(compound 2)

White solid compound (59% yield), m.p. 159-161oC; ^1H (CDCl_3 200MHz): δ 8.1 (d2H), 7.6 (t 1H), 7.3 (t 1H), 7.2 (d 1H) aromatic protons, 6.3 (dNH), 4.9 (m 1H) asymmetric proton, 3.8 (s3H), 1.6 (d3H); ^{13}C (CDCl_3 200MHz) δ 173.34, 167.52.89, 134.56, 128.100, 126.33, 126.28, 177.82, 115.87, 53.17 for CH, 50.21 for OCH₃; IR (KBr) 3240 (NH), 1752.09 (CO ester), 1680.23 (CO Oxazine ring), 1560 (C=N).

2-(N-Isoleucinyl methyl ester)-1,3-Benzoxazine-4- one(compound 3)

White crystalline solid (60% yield), m.p. 127-128 oC; ^1H (CDCl_3 200MHz) δ 8.03 (d 1 H), 7.58 (t1H), 7.30 (t1H), 7.16 (d 1 H) Aromatic protons, 6.42 (dNH), 3.82 (s3H), 1.49 (m2H), 1.30 (m 1 H asymmetric proton), 0.98 (m2x3H); ^{13}C (CDCl_3 200MHz) 172.73, 167.45, 158.62, 154.01, 134.63, 128.08, 125.89, 117.82, 115.85, 58.85, 52.90, 38.06, 25.52, 15.77, 12.08; IR (KBr) 3235.86 (NH), 1751.17 (CO ester), 1677.26 (CO Oxazine), 1603.35 (C=N); Anal. Cal. for C₁₂H₁₅N₃O₃; 62.06, H; 5.14, N; 10.21 Found, C; 62.16, H; 6.31, N; 9.70.

2-(N-Leucinyl methyl ester)-1,3-Benzoxazine-4-one(compound 4)

White crystalline solid (54% yield) m.p. 124-125 oC; ^1H (CDCl_3 200MHz) δ 8.07, (d 1 H), 7.75 (t 1 H), 7.29 (t 1 H), 7.29 (t 1 H), 6.25 (d 1 H) Aromatic protons, 6.23 (dNH), 4.95 (m asymmetric proton), 3.80 (sOCH₃), 1.79 (m2x3H); ^{13}C (CDCl_3 200MHz) 174.09, 167.47, 158.52, 154.06, 134.60, 128.10, 126.48, 125.87, 117.84, 116.04, 115.83; IR (KBr) 3240.49 (NH), 1751.67 (CO ester), 1618.66 (C=N).

2-(N-Methionyl methylester)-1,3-Benzoxazine-4-one(compound 5)

The product was solid compound 40% yield, m.p. 130-131 oC; ^1H (CDCl_3 200M) δ 11.4 (dNH), 8.1 (t 1 H), 7.6 (t 1 H), 7.3 (d 1 H) Aromatic protons, 6.2 (sNH), 5.0 (mCH asymmetric proton), 3.8 (s3H of OCH₃), 2.6 (q 2H of CH₂S), 2.38 (m2H of CH₂C), 2.2 (s3H of CH₃S), ^{13}C (CDCl_3 200MHz); 171.40, 167.47, 162.74, 161.41, 155.10, 150.93, 137.05, 134.29, 132.22, 128.27, 126.86, 126.11, 125.89, 124.24, 124.20, 117.74, 61.68 (OCH₃) one signal, 54.84, 53.32 at 32.07 (SCH₃), 30.151 IR (KBr) 3240.76 (NH), 1753.04 (CO), 1618.6 (C=N), The open compound gave about 35% yield with m.p. 128-160 oC and $^1\text{H NMR}$ spectrum showed signals at 4.3 (q2H) and triplet at 1.3 ppm, together with the rest protons of the compound. $^{13}\text{C NMR}$ spectrum confirms the open structure through the signal at 15.89, 14.63 related to the CH₃ of -OCH₂CH₃.

2-(N-phenylalanyl methyl ester)1,3 benzoxazine-4-one (compound 6)

White crystalline solid (65% yield), m.p. 125-125 oC; ^1H (CDCl_3 200MHz) δ 8.1 (q2x1H), 7.6 (m2x1H), 7.3 (m2x1H), 7.1 (q2x1H) Aromatic protons, 6.1 (qNH), 5.2 (m1H asymmetric proton), 3.8 (d3H of OCH₃), 3.33 (dofd2H with asymmetric CH) ^{13}C ; CDCl_3 200MHz) 171.5, 167.1, 157.5, 153.7, 135.3, 134.312 9.4, 128.8, 127.8, 127.7, 127.4, 125.7, 117.5, 115.6, 54.8, 52.8, 37.5

This compound showed two forms which when heated to 60 oC showed the following resonating signals: 171.81, 167.0, 158.06, 154.44, 135.96, 134.50, 1229.39, 129.22, 128.44, 127.83, 126.14, 118.37, 115.97, 55.62, 52.98, 38.35; IR (KBr) 3379.38 (NH), 1774.57 (CO ester) 1605.18 (C=N), Anl. Calc CHN, C; 66.66, H; 4.96, N; 8.64, Found, C; 66.72, H; 5.09, N; 8.53

2-(N-Valinyl methyl ester)-1,3-Benzoxazine-4-one (compound 7)



Sold compound (63%yield),m.p.159-161 oC;¹H (CDCl₃)200MHz) δ8.0(m1 H), 7.7 (m1H), 7.4(m1H), 7.0 (m1H) Aromatic protons showed two forms, 3.9(m1Hof CH), 3.8(d2x3HofOCH₃),2.2(m1H), 1.4(m1H), 1.0(m2x3H) of CH₃. This compound showed simplified spectrum when heated to 403K temperature which is fastening the enamine-amine exchange.

The trimer (the cyanate trimerization)

1-The ethyl cyano salicylate

¹HNMR spectrum gave the following signals:

10.89(sOH),8.05(d1H),7.64,6.5(m2H),7.39(t1H),4.43(q2H),1.44(t3H) which is consistent with sigma Aldrich ¹³CNMR;163.66for estercarbonyl,15 1.82for carbon 2,134.67C₆, 133.17forC₄, 127.47forC₅,121.16 forC₁,117.14 forC₃,108.86forC=N,62.34, 14.53 for CH₂, CH₃, respectivelyIR (neet) showed strong absorption peak at 22.94 related to C=N triple bond.

2-The trimer

This compound was prepared from the reaction of(1 g.) of ethyl cyanosalicylate with one drop of triethylamine at room temperature, the solid was recrystallized from petroleum ether(60-80 oC),95%yield, mp.97-99oC(published:97-98oC

¹HNMR (CDCl₃) 8.1 (m1H), 7.8 (m1H), 7.5 (m1H), 7.4 (m1H) aromatic protons showed more than one form,4,3(m2H),1.2(3s for three types ofCH₃ protons; ¹³CNMR(CDCl₃200MHz) 167.91, 164.39, 160.65, 154.37, 150.78, 135.6, 134.84, 134.16, 132.85, 128.49, 127.57, 127.18, 126.57, 123.81,123.71,123.22,117.02 which showed more than one type of aromatic carbons indicating the non planarity of these aromatic rings, 61.78,14.46 for -OCH₂,CH₃ respectively; IR(KBr) showed 1724.0cm⁻¹ forester,1613cm⁻¹forC=N.

2-(N-Prolinyl methyl ester)-1,3- Benzoxazine-4-one(compound8)

Solid white crystalline compound(62% yield),mp.132-133 oC.

¹HNMR; δ 8.15(q2types ofH),7.36 (m1H), 7.28 (m1H), 7.16 (m1H), 4.85,4.41 (twotypes of CH), 4.72 (m part of the praline ring nearest toN atom(ene-amine interchange)4.66(d2x3H),2.10(m proline rotions).

¹³CNMR(CDCl₃)172.15,171.91,167.13,166.89

(different types of C=O) (C₂,C_{8a}),134 .21, 134.129 C₅ (two types), 127.93, 127.88 C₇ (two types), 125.87,125.77 C₆ (two types), 117.84.117.65 C_{4a} (two types), 115.85, 115.63C₈ (two types), 60.08, 59.45-OCH₃ (two types,53.05, 52.78 for praline carbons next to nitrogen,48.63,46.98for praline ring carbons,30.97,30.0 for other praline ring carbons,23.99,23.55 two types of the rest praline carbons.

Heating the compound to 60 oC the NMR showed the following resonating signals ;172.05,154.30,134.0,128.20,118.35,115.75 as sigle signals together with the following aliphatic carbons60.01,59.91(two signals for -OCH₃,52.68,48.35,47.4(brod signal),30.30(broad signal), 23.92 which means thatsome carbons becomes single signal due to collecience temperature while the broad signals were near to collecience.

The IR spectrumshowed the following absorption signals; 1748.42 Cm⁻¹for the este rmoiety,1672 Cm⁻¹for C=N of oxazine ring,Anal.Calc forCHN,C;61.31,H;5.14,N;10.21,Found,C;61.28,H;5.21.N;10.27

2-(N-3-Amino pyridyl)1,3-Benzoxazine-4-one (compound9)

Bronish yellow powder(70% yield),mp.203-204 °C.

¹HNMR(DMSOd₆ 200MHz)10.96(broad NH),8.75(d ortho toNH),8.66(d para to NH),7.8(d orthotoNH),7.9(d meta to NH of the praline ring),7.81(d1H),7.74(m1H),7.4(m1H),6.97(d1H) Aromatic protons.

¹³CNMR(DMSOd₆);C₄C=O at167.34,160.36,159.57 for non protonated carbons,153.51for C_{8a},C₂, 144.90 for C₁₀.,142.54 forC₁₄,134.0 forC₇,128.18 for C₅, 126.21 forC₁₃,124.81 forC₆,122.62 forC₁₂,119.47 for C_{4a},115.23 for C₈.

IR (KBr) cm⁻¹3413.70 NH,1689.30, 1624.06, 1609.12,1557.82 for C=N,C=C Aromatic respectively.

Preparation of Compound 10

This compound gave the lowest yield(10%) due to the resonance withdrawal effect of the amino pyridine ring. The compound showed high mp.,above 300 °C and was insoluble in any common solvent except hot DMF and was recrystallized from acetic acid.The ¹HNMR spectrum (DMSOd₆) Heated to4 20K) showed the following resonating signals δ,8.79(broad),8.50,8.45 as broad signals,6.93(broad for NH). Anal.calc. for CHN, C; 65.27.H; 3.79.N; 17.56, Found, C;53.87, H; 4.71.N; 28.33, The calculated value did not fit with oxazine structure,So we suggest that the compound is pyridylcarboimide and not an oxazine type.

¹HNMR of compound10 gave the fowling resonating signals δ 8.3(d),6.6(d),4.2 for NH while ¹³CNMRDMSO heatedto470K)gave the following signals170.88,149.41 ,14.04, 145.24, 137.45,134.03, 114.21, 113.82

The IR (KBr) gave the following absorption Cm⁻¹; 3436.32 NH,1650.62,1601, 1507.98 for C=N,C=C of pyridine ring.


Antiplatelet measurements

Venous blood was collected from drug free volunteers into trisodium citrate 22.0g/l. Ethics approval was obtained from LaTrobe university Human ethics committee (HREC Number 06-16). The whole blood was centrifuged at 130g for 15 min at room temperature to obtain platelet rich plasma (PRP). The remaining blood was centrifuged for 10 min at 820g in order to obtain platelet poor plasma (PPP). Platelet aggregation was determined by the optical method in two-channel platelet aggregometer (Chrono-Log). Assays were carried out at 37 °C and had a total volume of 500 ml. After addition of the test compound and agonist. Stirring rate was 1000 rpm with the PRP and test compound being pre-incubated for 2 min before the addition of the appropriate agonist. The agonists used ADP (final concentration 10 μM) and collagen (final concentration 4 mg/ml).

Test compounds were dissolved in ethanol or DMSO depending on solubility and added in 3 ml volumes for ethanol and 2 ml volume for DMSO. The samples dissolved in DMSO were added in 2 ml volumes to ensure that the final concentration of DMSO was kept below 0.5 (v/v) which made certain that the DMSO would not influence platelet aggregation. Aggregation was recorded after the addition of the agonist and results were compared to platelet aggregation in the presence of an equivalent amount of test vehicle (Ethanol or DMSO). The concentration of compound at which the aggregation was inhibited by 50% (IC₅₀) was determined as the average of multiple determination (Three or more) where platelet aggregation was reduced by 50%.

Results and discussion


All compounds except compound (7) gave a trace amount of an open chain compound through their NMR of the crude products which shows the resonating signals of the ethoxy group protons at δ 1.3-1.4 ppm as triplet and quartet at 4.34 ppm. This open compound of each was not cyclized even in refluxing of the crude product for 4h. which means that the following structure prevents the cyclization.



The lone pair of electrons resonates to a form which causes the NH proton far away from the carbonyl group to be cyclized. These traces of open compounds were removed during recrystallization. While in methionine products it was about 50% of the crude product which could be easily identified.

This finding was supported by other researchers who worked on similar compounds¹². It was also found that chirality and anisochrony (magnetic non-equivalence) as a result of chirality some of the amino acid moieties showed magnetically non-equivalent protons and ¹³C chemical shifts for chemically equivalent groups¹⁴.

The ¹H NMR and ¹³C showed double signals due to the imine structures. The following structure shows the following two forms:



It is worth noting here that our general procedure for the preparation of the oxazine compounds was the improved one while the indicated procedure before improvement³ gave 16% yield for the morpholino oxazine while using this improved method morpholino oxazine yield becomes 90% yield. This improvement will encourage researchers and the industry to use this method in synthesizing these important compounds.



Some selected samples of the oxazine amino acid esters were tested for their antiplatelet effect and were found to have poor action but 3-amino pyridyl compound(9) gave significant effect among the tested compounds.

The trimer preparation method is also novel one because it was previously prepared by refluxing ethyl salicylate with cynuric chloride in 73% yield¹³ while in our method no need for using cynuric chloride.

Acknowledgment

The author would like to thanks Endeavour Australian scholarship team for offering the postdoctoral fellowship and thanks also due to LaTrobe University School of Pharmacy and Applied Science for providing the facilities to do this work.

References

1. W.Riad , J. Nenninger and J.W. Bats . Chem. Ber , 118 , 4707 (1985).
2. J.M.A. Al-Rawi and M.S. Al-Ajely , J. of Educ . and Sci , 10 , 39 (1990).
3. M.S. Al-Ajely and K.D. Sulaiman , J. of Educ. And Sci , 7 , 99 (1989).
4. A.H. Al-Mosusawi , J.M.A. Al-Rawi and M.S. Al-Ajely , Arab Gulf J. Sci, Res., 9, 1 (1991).
5. M.S. Al-Ajely and F.T.Al-Abachi, Iraq, patent No.2807 (2000).
6. H.A. Basheer PhD. Thesis , College of Education , Mosul University Mosul-Iraq (2000).
7. M.S.AIOAjely , H.A. Basheer, National J. of Chemistry 28 , 695 (2007).
8. M. Kaylane. Pritchaid , PhD. Thesis , LaTrobe University Bendigo , Melbourne,Victoria , Australia (2007).
9. W.H Pirkle ,. Pochapskly , T.C. J. Chrometogr , 89, 347 (1989).
10. Ibid , 369 , 175 (1986).
11. a-Grigat , Ernst , Puetter , Rolf-Farbentabriken Bayer AG, Germany. Chemische Bericht , 97 (11) 3012 (1964).
b-Grigat , Ernst , Cologne stammheim and Rolf. Patter vs patent 3,755,402 (1973).
12. Grigat, Est, Patter , Rolfshneided , Ka. Luedemeyer , Karlfried , US patent , 541092 2011 (1970)
13. A.W.Van Muijlwijk , A.P.G. Kieboom and H.Van Bekkum , Recueil , Journal of the Royal Netherland Chemical Society , 93,7,204 (1974).
14. D. Jasou . Mc Kerrow , PhD. Thesis , LaTrobe University Bendigo , Melbourne,Victoria , Austrelia (2007).